DUBLIN, April 18, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Analysis of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023" report to their offering.

This report assesses future trends in molecular imaging equipment revenues as well as growth in the number of unit shipments over the next few years. This will provide value to market participants that design and manufacture molecular imaging equipment.

Market participants will also be provided insights on recent industry and technology trends that are shaping the molecular imaging market. Radiopharmaceutical manufacturers will be provided with key insights on the evolving usage trends of workhorse FDG and Tc-99m radiopharmaceuticals and the increasing adoption of new radiopharmaceuticals across new clinical areas.

Companies that are in the process of developing software to improve quantitation accuracy, lower dosages, and reduce scan times for both PET and SPECT will be provided with key insights on how the molecular imaging market is growing as well as the factors that are required to facilitate greater adoption of PET and SPECT technologies.

Key Topics Covered:

1. Research Methodology

2. Executive Summary-Molecular Imaging

3. Executive Summary-Radiopharmaceuticals

4. Market Overview

5. Drivers and Restraints-Total Molecular Imaging Equipment Market

6. PET/CT Equipment Segment

7. SPECT/CT Equipment Segment

8. PET/MR Equipment Segment

9. Key Products and Participants

10. Latest Trends Among the Big Three Competitors-Philips Healthcare

11. GE Healthcare

12. Siemens Healthineers

13. Companies to Look Out For

14. Other Issues Impacting Growth Of Molecular Imaging

15. Key Technology and Industry Trends

16. Drivers and Restraints-Total Radiopharmaceuticals Market

17. PET Radiopharmaceuticals Segment

18. SPECT Radiopharmaceuticals Segment

19. Key Products and Participants

20. Key Companies to Look Out For

21. Key Industry Trends

22. Role of New Radiopharmaceuticals in Oncology

23. The Last Word

24. Appendix

25. Medicare Hospital Outpatient Prospective Payment System (HOPPS)

Companies Mentioned

- Advanced Accelerator Applications
- Bio-Nucleonics
- Blue Earth
- Bracco
- Cardinal
- Eckert & Ziegler Nuclitec
- Eli Lilly
- GE
- IBA Molecular
- Jubilant Draximage
- Kimberley-clark
- Lantheus
- MDS Nordion
- Mallinckrodt
- Mayo Clinic
- Molecular Dynamics
- Navidea
- NeuSoft
- PETNET
- Pharmalucence
- Philips
- Piramal
- Siemens Healthineers
- Spectrum
- Toshiba
- UltraSPECT

For more information about this report visit http://www.researchandmarkets.com/research/5mxv25/analysis_of_the

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets